Investigational drug · Phase 3
Oregovomab
Also called: MAb-B43.13
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Peritoneal Cancer, Ovarian Cancer, Fallopian Tube Neoplasms.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
17
Any phase or sponsor naming "Oregovomab"
First trial start
2020
Aug 25, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Oregovomab", any sponsor or status.
- Phase 213
Conditions studied
As listed on its trial records.
- Peritoneal Cancer
- Ovarian Cancer
- Fallopian Tube Neoplasms
- Peritoneal Carcinoma
- Ovarian Serous Adenocarcinoma
- Recurrent Ovarian Cancer
- Recurrent Epithelial Cancer of Ovary
- Recurrent Epithelial Ovarian Cancer
- Recurrent Fallopian Tube Cancer
- Recurrent Carcinoma of Ovary
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Oregovomab" as an intervention, largest first.
- Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking SurgeryPivotal-lookingActive, not recruiting
CanariaBio Inc.Industry
NCT04498117 · 615 participants · Start Aug 25, 2020 · Primary completion Dec 26, 2026
Drug: Oregovomab; Paclitaxel and 3 more · For: Carcinoma, Ovarian Epithelial; Ovarian Neoplasms; Ovarian Cancer and 7 more
Sites: Phoenix, Arizona; Tucson, Arizona; Concord, California · 148 sites in all
- Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and ChemotherapyPivotal-lookingStatus unknown
AltaRexIndustry
NCT00003634 · 400 participants (planned) · Start Apr 1998
Drug: oregovomab · For: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Sites: Berkeley, California; Los Angeles, California; Orange, California · 46 sites in all
- Clinical Trial for Ovarian Cancer (OvaRex®)Pivotal-lookingTerminated
Unither PharmaceuticalsIndustry
NCT00050375 · 354 participants · Start Dec 2002
Drug: oregovomab · For: Ovarian Cancer
Sites: Huntsville, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 62 sites in all
- Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal CancerPivotal-lookingStatus unknown
AltaRexIndustry
NCT00004064 · 102 participants (planned) · Start Nov 1998
Drug: oregovomab · For: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Sites: Newport Beach, California; Fort Myers, Florida; Orlando, Florida · 16 sites in all
- Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian CarcinomaPivotal-lookingTerminated
Unither PharmaceuticalsIndustry
NCT00034372 · 102 participants · Start Sep 2000
Drug: oregovomab · For: Ovarian Neoplasms
Sites: Newport Beach, California; Stanford, California; Orlando, Florida · 17 sites in all
Quest PharmaTech Inc.Industry
NCT01616303 · 97 participants · Start Jun 15, 2012 · Primary completion Jun 15, 2015
Drug: Carboplatin; Paclitaxel and 1 more · For: Ovarian Neoplasms
Sites: Farmington, Connecticut; South Bend, Indiana
- Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian CancerActive, not recruiting
CanariaBio Inc.Industry
NCT05605535 · 88 participants (planned) · Start Feb 7, 2023 · Primary completion May 15, 2027
Drug: Oregovomab; Paclitaxel and 2 more · For: Ovarian Neoplasm Epithelial; Ovarian Cancer; Fallopian Tube Neoplasms and 2 more
Sites: Visakhapatnam, India; Vadodara, India; Belagavi, India · 14 sites in all
Yonsei UniversityAcademic, hospital or other
NCT05407584 · 56 participants (planned) · Start Jul 5, 2022 · Primary completion May 2024
Drug: Orevogomab+PLD; Orevogomab+Paclitaxel · For: PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
Sites: Seoul, South Korea
- Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian CancerActive, not recruiting
CanariaBio Inc.Industry
NCT04938583 · 54 participants (planned) · Start Mar 17, 2021 · Primary completion Oct 30, 2025
Drug: Oregovomab; Bevacizumab and 2 more · For: Ovarian Cancer by FIGO Stage; Ovarian Cancer Stage III; Ovarian Cancer Stage IV
Sites: Seoul, South Korea; Daegu, South Korea; Seongnam-si, South Korea · 6 sites in all
- Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer TreatmentTerminated
Unither PharmaceuticalsIndustry
NCT00086632 · 40 participants · Start Jul 2004
Drug: oregovomab · For: Ovarian Cancer
Newest research
PubMed records naming it or its code names, newest first.
- Long-term survival analysis of a randomized phase II study of front-line chemo-immunothe-rapy with carboplatin-paclitaxel using oreg-ovomab indirect immunization in advanced ovarian cancer (QPT-ORE-002).
Terranova C, Salutari V, Plotti F, et al. · Int J Gynecol Cancer 2026
- A Phase Ib Study of Indirect Immunization with Oregovomab and Toll-like-Receptor-3 Stimulation with Hiltonol® in Patients with Recurrent Platinum-Resistant Ovarian Cancer.
Holloway RW, Temkin SM, Gordon SW, et al. · Curr Oncol 2025
- OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer.
Park J, Cho HW, Lim MC, et al. · Future Oncol 2024
- Front-line chemoimmunotherapy for treating epithelial ovarian cancer: Part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen.
Yang ST, Chang WH, Chou FW, et al. · Taiwan J Obstet Gynecol 2024
- Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125.
Yang ST, Chang WH, Chou FW, et al. · Taiwan J Obstet Gynecol 2023
- Oregovomab Plus Chemo in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5/GOG-3035).
Gregory SN, Sarvestani AL, Ryan CE, et al. · Ann Surg Oncol 2023
Also in development for Peritoneal Cancer
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- KAND567FractalkinePhase 21 trial
Novakand Pharma AB · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.